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Abstract
Purpose of Review Atrial fibrillation (AF) is the most common arrhythmia in adults. The number of patients with AF is anticipated
to increase annually, mainly due to the aging population alongside improved arrhythmia detection. AF is associated with a
significantly elevated risk of hospitalization, stroke, thromboembolism, heart failure, and all-cause mortality. Echocardiography
is one of the key components of routine assessment and management of AF. Therefore, the aim of this review is to briefly
summarize current knowledge on “novel” echocardiographic parameters that may be of value in the management of AF patients.
Recent Findings Novel echocardiographic biomarkers and their clinical application related to the management of AF have been
taken into consideration. Both standard parameters such as atrial size and volume but also novels like atrial strain and tissue
Doppler techniques have been analyzed.
Summary A number of novel echocardiographic parameters have been proven to enable early detection of left atrial dysfunction
along with increased diagnosis accuracy. This concerns particularly experienced echocardiographers. Hence, these techniques
might improve the prediction of stroke and thromboembolic events among AF patients and need to be further developed and
disseminated. Nonetheless, even the standard imaging parameters could be of significant value and should not be discontinued in
everyday clinical practice.
Keywords Atrial fibrillation . Echocardiography . Tissue Doppler . Atrial strain . Atrial volume index . Biomarkers
Introduction
Atrial fibrillation (AF) is the most common arrhythmia in
adults. The predicted prevalence of AF by 2030 is more than
15 million Europeans [1]. The incidence of AF increases with
age, reaching over 15% by the age of 80, especially in the
presence of various cardiovascular risk factors [2]. In the last
2 decades, over 60% increase in AF-related hospitalization
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has been observed. AF is also associated with progression of
diastolic and systolic heart failure, impaired quality of life, and
increased all-cause mortality [3–5]. Importantly, AF may not
cause evident symptoms which makes both diagnosis and
treatment a challenge. Indeed, asymptomatic AF has been
shown to be one of the reasons for transient ischemic attacks
(TIA) or cryptogenic ischemic strokes [6]. Consequently, bet-
ter understanding of AF, particularly detection of AF seems to
be of utmost importance to reduce the number of AF-related
complications, particularly stroke [7, 8]. There is also an in-
creasing focus on an integrated or holistic approach to AF
management, which has been associated with improved out-
comes [9, 10].
The underlying mechanisms of AF are still not fully ex-
plained, but may include heterogeneous factors leading to
electrical, structural, and mechanical remodelling of the left
atrium (LA) [11]. Despite continuous efforts to re-establish
sinus rhythm, either with drugs or AF ablation, the only
well-proven method to improve prognosis in AF patients re-
mains systemic anticoagulation, which reduces the risk
of stroke and all-cause mortality [12]. In addition, there
is often no correlation between arrhythmia onset and stroke
which further complicates our understanding of AF patho-
physiology [13].
Consequently, there has been a greater focus on new diag-
nostic imaging techniques and new parameters to help better
prediction, detection, and treatment of AF in clinical practice.
There are multiple imaging modalities and increasing oppor-
tunities with cardiac investigations, such as echocardiography.
Indeed, echocardiography is becoming an essential compo-
nent of endovascular invasive procedures such as ablation, left
atrial appendage closure, or mitral valve regurgitation
treatment [14].
The aim of this review article is to provide an overview of
“novel” echocardiography parameters which may be of value
in the diagnostic workup and management of patients with
AF.We put emphasis on clinically useful parameters and tech-
niques which are gaining in popularity, with the potential for
improving patient management.
Atrial Size and Volume
The incidence of AF is associated with structural remodelling
and dilatation of LA [15, 16]. It is less clear whether AF is a
consequence of LA remodelling and dilatation or vice versa,
though both mechanisms are feasible. The precise underlying
pathophysiology of LA remodelling is also not entirely clear
but include local and systemic inflammation, atrial fibrosis,
atrial enlargement, altered autonomic tone, and anatom-
ical and electrical changes [17, 18]. Such structural
changes and fibrosis increase the surface for multiple
wave propagation, causing AF both to emerge and become
more persistent [19].
Atrial fibrosis has been shown in both lone AF and AF
secondary to mitral valve diseases. Fibrillar collagen deposits
substitute, as a repair process, degenerating myocardial cells
causing interstitial expansion and thus deteriorate atrial elec-
trical and mechanical function [20]. LA fibrosis has been
shown by delay-enhanced magnetic resonance imaging (DE-
MRI) [21, 22]. For example, the Utah scale describes the
degree of LA fibrosis (Utah I: minimal fibrosis; Utah IV: ex-
tensive fibrosis), which is of clinical importance because the
degree of fibrosis may impact on the efficacy of AF ablation
[23, 24]. Indeed, observed AF recurrences were more frequent
in patients with more advanced LA fibrosis (75%) compared
with those with minimal enhancement in DE-MRI (14%) [22].
Furthermore, a significant correlation has been shown recently
between LA diastolic function obtained in speckle tracking
echocardiography and low amplitude potential area measured
with electroanatomical mapping. These findings pointed to
use speckle tracking echocardiography as a valuable and use-
ful method in the assessment of LA fibrosis [25].
Consequently, the assessment of LA fibrosis has been pro-
posed as part of the workup for patients undergoing AF
ablation.
Patients with recurrent AF have essentially greater left atri-
al diameters compared with those with sinus rhythm. Indeed,
LA enlargement seems to be the key determinant of successful
rhythm control in patients with AF. For example, a meta-
analysis of 3700 patients [26] and other reports [27–29] clear-
ly show that a dilated LA significantly increases the risk for
AF recurrence. External cardioversion and catheter ablation in
AF patients with LA diameter of 50–55 mm are of limited
value [30]. LA diameter as assessed by transthoracic echocar-
diography in parasternal long axis view (PLAX) with a diam-
eter of > 43 mm was the cutoff value for prediction of parox-
ysmal AF recurrence after catheter ablation [31]. The
AFFIRM study also showed that recurrent AF occurs more
often with larger LA diameter, with a hazard ratio (HR) for AF
relapse of 1.21 for LA diameter of 4.1–4.5 cm and 1.32 for
LA > 5.5 cm [32].
Despite the fact that LA diameter is commonlymeasured in
clinical practice, its predictive value might be limited com-
pared with the assessment of the LAVolume Index (LAVI).
This is mainly driven by possible misleading in antero-
posterior linear dimension due to distorted atrium.
Furthermore, LAVI was shown to be more strongly associated
with cardiovascular diseases compared with the linear dimen-
sion [33, 34]. The latter could be obtained using both two- and
three-dimensional echocardiography [35, 36]. Importantly, as-
sessment of LAVI combined with various biomarkers (D-di-
mer, prothrombin, thrombin-antithrombin complex, and fibrin
monomer) may be of value in identifying patients with under-
lying (but undetected) AF and cryptogenic stroke [37]. LAVI
was also shown to be a predictor of AF recurrence after mitral
valve (MV) surgery and successful external cardioversion.
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LAVI > 39 mL/m2 was an independent predictor for AF after
MV surgery [38]. For those AF patients who were externally
cardioverted, LAVI showed higher predictive value for AF
recurrence compared with a simple assessment of LA diame-
ter (AUC 0.78 vs 0.56 respectively, p = 0.003) [39].
Dimensions of the right atrium (RA) may also be of clinical
importance in patients with AF. Increased RA volume index
(RAVI) may affect the efficacy of catheter ablation. Indeed, it
has been shown that in patients being 3 months after the ab-
lation RAVI > 78 mL/m2 predicted AF relapse with 74% sen-
sitivity and 68% specificity [40].
Left Atrial Strain
The term “strain” means deformation of the myocardium and
is used to describe the mechanical function of the atrium or
ventricle throughout the cardiac cycle. In the atria, reservoir,
conduit, and booster function can be assessed. The maximum
myocardial shortening of LA during atrial systole is defined as
the peak atrial contraction strain (PACS) and the veloc-
ity of this deformation is termed the “strain rate.”
Maximal deformation of the LA myocardium during
systole of the left ventricle has been described as peak
atrial longitudinal strain (PALS) and reflects the reser-
voir function of the chamber. For echocardiographic measure-
ments in AF, similar RR intervals and heart rate of < 100/min
are important, whereas the number of averaged cardiac cycles
is of less value [41].
Left Peak Atrial Longitudinal Strain
Left peak atrial longitudinal strain (PALS) is perceived as a
parameter of atrial distension that immediately reflects any
changes in heart rhythm [42]. In one prospective study,
PALS (see Fig. 1) was measured before and soon after cardio-
version. The parameter increased immediately following
the restoration of sinus rhythm by electrical cardiover-
sion (11.9 ± 1 vs 15.9 ± 1.3 respectively). In addition,
among patients with a higher increase in PALS, the
incidence of AF recurrence was lower over a 6-month
observation; indeed, the difference in strain, obtained by
regression analysis adjusted for age, sex, and body mass
index (BMI), was shown as a predictor of sinus rhythm
maintenance [42]. Several studies have showed that PALS
may be of value in predicting successful AF catheter ablation
(see Table 1) [43–46].
Conversely, reduced PALS is associated with a higher risk
of secondary AF (after MV surgery or CABG [47–50]).
Importantly, lower PALS is linked not only with AF develop-
ment or recurrence but also with the higher risk for stroke in
paroxysmal, permanent, and persistent AF [46, 51]. PALS is
predictive of the risk of AF in patients with cryptogenic
stroke [52].
LA Dispersion
Dispersion is defined as a loss of coordinated myocardial con-
traction (dyssynchrony). The index of LA dispersion has been
proposed to accurately measure the extent of dyssynchrony
and potential impact on LA function, probability of arrhyth-
mia (in particular AF) and prognosis (e.g., risk of stroke). The
index of LA dispersion has been defined as standard deviation
(SD) of the time to the PALS in 12 LA segments, projected in
the 2 apical views (see Fig. 2), which correlates with LA
remodeling and brain natriuretic peptide (BNP) concentra-
tions [53]. A negative correlation between the index of LA
dispersion and PALS (r = − 0.44) may suggest that the con-
tractility of the LA is lower in a dyssynchronized LA [53]. On
multivariate analysis, adjusted for the pre-cardioversion clini-
cal and echocardiographic variables, the index of LA disper-
sion was an independent predictor of 1-year AF recurrence
following cardioversion [54]. Indeed, dispersion of time to
PALS may be of value in the prediction of sinus rhythmmain-
tenance. The parameter lower than a cut-off point of 128 ms
predicted sinus rhythm at 6 months after CV with 66% accu-
racy [55]. Furthermore, LA mechanical dispersion, defined as
SD of contraction times of 18 LA segments, was reported to
predict AF recurrence after catheter ablation (cutoff value of
24 ms, sensitivity of 77%, and a specificity of 85%, AUC
0.88) [56]. Thus, LA dispersion is in different works assessed
as SD of 12 or 18 segments contraction durations or the max-
imal difference of contraction durations in 12 atrial segments.
The electrical response to cardioversion (namely sinus
rhythm) may not be consistent with endocrine and mechanical
remodelling responses of the heart, at least in the early phase
(e.g., 1 month after cardioversion). For example, patients with
sinus rhythm 1 month after cardioversion had similar pro-
atrial natriuretic peptide (proANP) levels and PALS compared
with those with persistent AF, even though sinus rhythm
restoration was associated with lowering of the LAVI;
thus, alternations in LA volume may precede changes in LA
remodeling [57].
LA Stiffness
LA stiffness, defined as the ratio of delta pressure and volume
in the left ventricle (LV), can be easily computed when
pressure/volume curves are obtained during invasive proce-
dure, e.g., pulmonary veins isolation. LV longitudinal strain
has been identified as the only independent predictor of LA
stiffness, and the addition of a LV stiffness parameter (based
on MV deceleration time [58]) to the LA stiffness predictor
increases sensitivity and specificity of AF recurrence predic-
tion up to 72% and 75%, respectively [53]. Because systolic
parameters in AF patients are not easily reproducible and di-
astolic measures are better validated against invasivemeasure-
ments, LA strain may have promising use clinically [41].
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Two-dimensional speckle-tracking may also be valuable in
predicting paroxysmal AF, especially in patients with ische-
mic stroke or TIA [59]. Early diastolic strain rate (SRe) and
global longitudinal displacement (GLD) of the left ventricle
were significantly lower in patients with paroxysmal AF com-
pared with those without arrhythmia [6]. These parameters
were retrospectively assessed in 205 patients who survived
acute cerebrovascular ischemia (cryptogenic stroke or TIA),
were in sinus rhythm, and underwent echocardiography ex-
amination: none of the conventional echocardiographic pa-
rameters but lower GLD and lower SRe were significantly
associated with paroxysmal AF [6].
Due to its high sensitivity in determining subtle abnormal-
ities, two-dimensional speckle-tracking can provide an early
assessment of left ventricular (LV) diastolic dysfunction given
there is an association with reduced reservoir, conduit, and LA
Fig. 1 a, b Representative strain
curve of LAwith R-R gating. The
functional phases of LA
mechanics are shown in sinus
rhythm (1A) and atrial fibrillation
(1B). In atrial fibrillation peak, the
atrial contractile strain has
disappeared. Dotted line means
averaged peak LA strain. PALS,
peak atrial longitudinal strain;
PACS, peak atrial
contractile strain
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contraction. Therefore, the diagnosis can be established soon-
er than with the use of standard echocardiography measure-
ments [60]. Moreover, in impaired LA deformation visualized
by significant reduction of longitudinal systolic strain rate
(SRs), systolic strain (SR) and SRe have been independently
associated with the presence of left atrial appendage (LAA)
thrombus; hence, speckle-tracking might provide an addition-
al, clinically practical tool in identifying patients at risk for
LAA thrombus formation [61].
Total Conduction Time
The stage of atrial fibrosis correlates with AF-burden, defined
as the percentage of time spent in arrhythmia [62–64]. This
degree of atrial fibrosis can be estimated by total atrial con-
duction time (PA-TDI) which is the time interval between the
onset of P-wave in lead II of the ECG on echocardiographic
images to the peak A´-wave of the lateral atrial wall on the
tissue Doppler tracing. One analysis that assessed the relation-
ship between LA reservoir strain and PA-TDI in AF patients,
as compared with those without AF, showed that patients with
paroxysmal and persistent AF had significantly longer PA-
TDI and a progressive decline in LA reservoir [65]. LA reser-
voir function correlated negatively with PA-TDI which may
suggest that the burden of LA fibrosis and LA structural re-
modelling affects the progression of AF [65].
PA-TDI can also be useful in the prediction of new-onset
AF after acute myocardial infarction. LA maximal volume
(HR 1.07), total LA ejection fraction (HR 0.96), and PA-TDI
duration (HR 1.05) were independent predictors of new-onset
AF in patients after acute myocardial infarction [66].
Moreover, PA-TDI > 145 ms (93.8% sensitivity and 90.5%
specificity) was shown to predict AF in patients with crypto-
genic stroke [67]. Also, intra (left) atrial mechanical delay
obtained with simultaneous recording of Doppler waveforms
at two different sites (tissue Doppler echocardiography) may
predict AF recurrence [68].
Diastolic and Systolic Tissue Doppler Parameters
Simple and objective parameters defining the risk of arrhyth-
mia recurrence would be helpful in tailoring AF treatment. Ari
et al. investigated the predictive value of pre-cardioversion
tissue Doppler parameters which link systolic atrial (Aa) and
Fig. 2 The example of temporal analysis of LA contraction—two-
dimensional speckle-tracking based LA strain curves derived from a
four-chamber apical view. Each curve represents one of the six LAwall
segments; dotted line means averaged peak LA strain. White arrows
indicate time to peak atrial longitudinal strain from each of the
visualized 6 segments. Indices derived from the time to peak strain of
each segment are considered in dyssynchrony (dispersion) analysis.
Usually, the standard deviation of time to peak strain is taken (see
chapter: LA dispersion)
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systolic ventricular (Sa) functions with diastolic atrial
function—LV filling pressure (E/Ea). Preliminary results,
based on 127 patients showed that the indices were signifi-
cantly higher in the AF recurrence group compared with the
sinus rhythm group [69].
LA Appendage
In the healthy heart, the LA appendage (LAA) is a location for
reduced contractility and stasis within the LA. Thus, in spe-
cific circumstances (e.g., in patients with AF), it is often the
location for thrombus formation. Indeed, approximately 90%
of AF-related thrombi are localized in LAA. The shape of the
LAA can be classified into four groups: wind-sock, chicken-
wing, cauliflower, cactus-like (see Fig. 5) [70]. Compared
with non-chicken morphology, the chicken-wing morphology
of LAA was found to be associated with significantly de-
creased thromboembolic risk in AF. Conversely, compared
with chicken-wing, cactus and windsock were associated with
a 4-fold and cauliflower with an 8-fold increase in stroke or
TIA risk [71].
LAA Contraction
Evaluation of LAA contraction is crucial to assess the poten-
tial for thrombus formation. Under normal circumstances, that
is in sinus rhythm and when contractility of the LA is pre-
served, the apex of LAA almost obliterates. The emptying
velocity, that is highest in the proximal part of LAA, ranges
from 50 to 83 cm/s [72]. Velocities < 40 cm/s are considered
as increasing the risk for stroke [73]. Of note, LAA emptying
velocity should be measured at the LAA orifice up to 2 mm
inside LAA due to its dependency on the measurement depth
[74]. Velocities < 20 cm/s (usually with the presence of spon-
taneous echo contrast) have been associated with high throm-
boembolic risk (see Fig. 3) [73].
Even in low CHADS2 score patients (≤ 1) LA emptying
velocity and LAA ejection fraction (LAAEF) were valuable
predictors of thrombus formation. For LAAEF measurement,
both disk summation method and endocardial border speckle
tracking (e.g., by velocity vector imaging) can be successfully
utilized [75, 76]. For thrombus prediction, AAEF of 21% (as
the cutoff value) showed 93% sensitivity and 96% specificity,
whereas the corresponding values for LAA emptying velocity
(cutoff value of 24 cm/sec) were 73% and 75% (AUC 0.73),
respectively [75].
Tissue velocity imaging has been used to assess the LAA
walls velocities (both in transthoracic (TTE) and transesoph-
ageal echocardiography (TEE)) and the risk of thrombus for-
mation [77]. Severe spontaneous echo contrast in LAA was
found with 72% sensitivity and 82% specificity if TDI mean
velocity was < 6.13 cm/s. On regression analysis, LAA tissue
Fig. 3 Pulse wave Doppler of LAAvelocity taken from the proximity of orifice of LAA. Different velocities represent graded risk of a thromboembolic
event. In the picture, LAA emptying velocity is above 40 cm/s indicating low risk of a thromboembolic event
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Doppler velocity was the only predictor of qualitative LAA
spontaneous contrast grade [78]. Moreover, LAAwall veloc-
ity assessed by spectral tissue Doppler can predict sinus
rhythmmaintenance after catheter ablation with 60% sensitiv-
ity and 91% specificity [43]
The higher the emptying velocity before CV is, the
higher the probability of sinus rhythm 1 year after CV
is, with the velocity exceeding 40 cm/s having 56%
sensitivity and 80% specificity [28]. Conversion of AF
to sinus rhythm is often accompanied by transient me-
chanical dysfunction of LAA, called atrial stunning.
Stunning is defined as LAA peak diastolic emptying
velocity lower than 20 cm/s [70]. Such stunning after
successful cardioversion may last from hours to
weeks—this is why anticoagulation is indicated for four
weeks afterward.
LAA in 3 Dimensions
Three-dimensional (3D) echocardiography seems to be very
helpful in LAA shape and detailed morphology assessment.
3D TEE is superior to 2D TEE in differentiating pectinate
muscles, thrombus, myocardium or calcification, lysis, and
structure mobility (see Fig. 4) [79]. Moreover, volumes or
LAA orifices are likely to be less underestimated in 3D com-
pared with 2D, and 3D tools can be utilized in automated
volume calculation [80–82]. LAA orifice is measured due to
easily obtainable views in 3D TEE [70, 80, 83]
Conclusions: Keeping It Simple
There are several “novel” echocardiographic parameters that
hold promise to be more accurate in the assessment of both
Fig. 4 Three-dimensional transoesophageal echocardiography utilization in the assessment of left atrial appendage. The 2D images are blurred (circle)
and the exploration of 3D reveals pectinate muscles (arrow) as the reason of 2D image inconsistency
Fig. 5 Four different left atrial
auricle (LAA) morphology
classification
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LA function and very early LA dysfunction and thus theymay
further improve prediction of AF, stroke, heart failure, or death
compared with standard echocardiographic indices. For now,
these parameters have not been included in standard echocar-
diography examination because they require an experienced
echocardiographer, have limited reproducibility, prolong the
time of examination, but most importantly have not been
shown to be substantially superior to very simple and easy
to use parameters that can be measured by everybody in rou-
tine clinical practice.
The best example of such an “easy” parameter is LA size
(perhaps also LA volume), and regardless of limitations asso-
ciated with a simple measurement of this parameter, it may
have robust clinical significance. Indeed, echocardiography
may become a crucial diagnostic tool to guide therapy in some
niche areas of clinical practice. For example, it may predict
AF, stroke, or both in patients with a history of cryptogenic
stroke and no evidence of AF. Two recent trials (NAVIGATE
ESUS and RE-SPECT ESUS) failed to show the benefit of
therapy with rivaroxaban and dabigatran respectively versus
aspirin for the prevention of recurrent strokes in patients with
the history of cryptogenic stroke [84, 85]. However,
subanalysis of the NAVIGATE ESUS trial showed that in
patients with LA diameter of more than 4.6 cm (the risk factor
for AF development) the risk of stroke at 1 year was signifi-
cantly lower for therapy with rivaroxaban (1.7%) than with
aspirin (6.5%) (HR 0.26; 95% CI, 0.07–0.94) [86].
Another niche area for echocardiography may be improved
stroke risk stratification in patients with AF and truly low risk
of stroke, that is CHA2DS2-VASc 0 in men and 1 in women.
For now, there is no clear evidence for the positive net clinical
benefit of oral anticoagulation (when balancing the risk of
stroke versus the risk ofmajor bleeding, particularly intracranial
hemorrhage) in such patients. However, “low-risk” is not ho-
mogenous and static and there may be some patients who
would benefit from anticoagulation. Indeed, one recent report
shows that oral anticoagulationmay be beneficial in very young
AF patients, e.g., those aged 35 or more with concomitant heart
failure (CHA2DS2-VASc = 1) [87]. Assessment of LA size (see
Fig. 5), volume, LAAmorphology (e.g., non-chicken morphol-
ogy) and perhaps also more sophisticated indices (e.g., PALS)
may help stratify stroke risk and guide anticoagulation in AF
patients presently perceived as being at a very low risk of
stroke.
Acknowledgements Jakub Gumprecht was supported by the Polish
Cardiac Society Club 30 Specialized Research Fellowship Grant for
Early Career Researchers.
Compliance with Ethical Standards
Conflict of Interest Gregory Lip declares he is a consultant for Bayer/
Janssen, BMS/Pfizer, Medtronic, Boehringer Ingelheim, Novartis,
Verseon, and Daiichi-Sankyo, and a speaker for Bayer, BMS/Pfizer,
Medtronic, Boehringer Ingelheim, and Daiichi-Sankyo. No fees are di-
rectly received personally.
Michał Mazurek has received consultant fees from Biotronik, Boston
Scientific, Medtronic, and St. Jude Medical/Abbott
All other authors declare no conflict of interest.
Human and Animal Rights and Informed Consent This article does not
contain any studies with human or animal subjects performed by any of
the authors.
Open AccessThis article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References:
Papers of particular interest, published recently, have been
highlighted as:
• Of importance
•• Of major importance
1. Zoni-Berisso M, Lercari F, Carazza T, Domenicucci S.
Epidemiology of atrial fibrillation: European perspective. Clin
Epidemiol. 2014;6:213–20. https://doi.org/10.2147/CLEP.S47385.
2. Allan V, Honarbakhsh S, Casas J-P, et al. Are cardiovascular risk
factors also associated with the incidence of atrial fibrillation?
Thromb Haemost. 2017;117(05):837–50. https://doi.org/10.1160/
TH16-11-0825.
3. Ehrlich JR, Nattel S, Hohnloser SH. Atrial fibrillation and conges-
tive heart failure: specific considerations at the intersection of two
common and important cardiac disease sets. J Cardiovasc
Electrophysiol. 2002;13(4):399-405. http://www.ncbi.nlm.nih.gov/
pubmed/12033360. Accessed June 10, 2019.
4. Wang TJ, Larson MG, Levy D, et al. Temporal relations of atrial
fibrillation and congestive heart failure and their joint influence on
mortality. Circulation. 2003;107(23):2920–5. https://doi.org/10.
1161/01.CIR.0000072767.89944.6E.
5. Darby AE. Management Of atrial fibrillation in patients with heart
failure. J Atr Fibrillation. 2014;7(2):1105. https://doi.org/10.4022/
jafib.1105.
6. Skaarup KG, Christensen H, Høst N, et al. Usefulness of left ven-
tricular speckle tracking echocardiography and novel measures of
left atrial structure and function in diagnosing paroxysmal atrial
fibrillation in ischemic stroke and transient ischemic attack patients.
Int J Cardiovasc Imaging. 2017;33(12):1921–9. https://doi.org/10.
1007/s10554-017-1204-1.
7. Lip GYH, Freedman B, De Caterina R, Potpara TS. Stroke preven-
tion in atrial fibrillation: past, present and future. Thromb Haemost.
2017;117(07):1230–9. https://doi.org/10.1160/TH16-11-0876.
8. Lip GYH, Banerjee, Amitava, Boriani G, et al. Antithrombotic
therapy for atrial fibrillation CHEST guideline and expert panel
report. 2018. https://doi.org/10.1016/j.chest.2018.07.040.
9. Lip GYH. The ABC pathway: an integrated approach to improve
AF management. Nat Rev Cardiol. 2017;14(11):627–8. https://doi.
org/10.1038/nrcardio.2017.153.
10. Pastori D, Pignatelli P, Menichelli D, Violi F, Lip GYH. Integrated
care management of patients with atrial fibrillation and risk of
Curr Cardiovasc Imaging Rep (2019) 12: 43 Page 9 of 12 43
cardiovascular events.Mayo Clin Proc. December 2018. https://doi.
org/10.1016/j.mayocp.2018.10.022.
11. Mathew ST, Patel J, Joseph S. Atrial fibrillation: mechanistic in-
sights and treatment options. Eur J Intern Med. 2009;20(7):672–81.
https://doi.org/10.1016/j.ejim.2009.07.011.
12. Lip GYH, Fauchier L, Freedman SB, et al. Atrial fibrillation. Nat
Rev Dis Prim. 2016;2(1):16016. https://doi.org/10.1038/nrdp.2016.
16.
13. Damluji AA, Al-Damluji MS, Marzouka GR, et al. New-onset ver-
sus prior history of atrial fibrillation: outcomes from the AFFIRM
trial. Am Heart J. 2015;170(1):156-163.e1. https://doi.org/10.1016/
j.ahj.2015.04.020.
14. Kim T-S, YounH-J. Role of echocardiography in atrial fibrillation. J
Cardiovasc Ultrasound. 2011;19(2):51–61. https://doi.org/10.4250/
jcu.2011.19.2.51.
15. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for
the management of atrial fibrillation developed in collaboration
with EACTS. Eur Heart J. 2016;37(38):2893–962. https://doi.org/
10.1093/eurheartj/ehw210.
16. Corradi D, Callegari S, Maestri R, Benussi S, Alfieri O. Structural
remodeling in atrial fibrillation. Nat Clin Pract Cardiovasc Med.
2008;5(12):782–96. https://doi.org/10.1038/ncpcardio1370.
17. Waldo AL. Mechanisms of atrial fibrillation. J Cardiovasc
Electrophysiol. 2003;14(12 Suppl):S267-S274. http://www.ncbi.
nlm.nih.gov/pubmed/15005213. Accessed June 10, 2019.
18. Weiss JN, Qu Z, Chen P-S, et al. The dynamics of cardiac fibrilla-
tion. Circulation. 2005;112(8):1232–40. https://doi.org/10.1161/
CIRCULATIONAHA.104.529545.
19. Liżewska-Springer A, Dąbrowska-Kugacka A, Lewicka E, Drelich
Ł, Królak T, Raczak G. Echocardiographic predictors of atrial fi-
brillation recurrence after catheter ablation: a literature review.
Cardiol J. 2013. https://doi.org/10.5603/CJ.a2018.0067.
20. Burstein B, Nattel S. Atrial Fibrosis: mechanisms and clinical rele-
vance in atrial fibrillation. J Am Coll Cardiol. 2008;51(8):802–9.
https://doi.org/10.1016/J.JACC.2007.09.064.
21. Daccarett M, Badger TJ, Akoum N, et al. Association of left atrial
fibrosis detected by delayed-enhancement magnetic resonance im-
aging and the risk of stroke in patients with atrial fibrillation. J Am
Coll Cardiol. 2011;57(7):831–8. https://doi.org/10.1016/j.jacc.
2010.09.049.
22. Oakes RS, Badger TJ, Kholmovski EG, et al. Detection and quan-
tification of left atrial structural remodeling with delayed-
enhancement magnetic resonance imaging in patients with atrial
fibrillation. Circulation. 2009;119(13):1758–67. https://doi.org/10.
1161/CIRCULATIONAHA.108.811877.
23. Akkaya M, Marrouche N, Higuchi K, et al. The degree of left atrial
structural remodeling impacts left ventricular ejection fraction in
patients with atrial fibrillation. Turk Kardiyol Dern Ars.
2014;42(1):11–9. https://doi.org/10.5543/tkda.2014.20726.
24. Chelu MG, King JB, Kholmovski EG, et al. Atrial fibrosis by late
gadolinium enhancement magnetic resonance imaging and catheter
ablation of atrial fibrillation: 5-year follow-up data. J Am Heart
Assoc. 2018;7(23):e006313. https://doi.org/10.1161/JAHA.117.
006313.
25. Pilichowska-Paszkiet E, Baran J, Sygitowicz G, et al. Noninvasive
assessment of left atrial fibrosis. Correlation between echocardiog-
raphy, biomarkers , and elec t roanatomical mapping.
Echocardiography. 2018;35(9):1326–34. https://doi.org/10.1111/
echo.14043.
26. Zhuang J, Wang Y, Tang K, et al. Association between left atrial
size and atrial fibrillation recurrence after single circumferential
pulmonary vein isolation: a systematic review and meta-analysis
of observational studies. Europace. 2012;14(5):638–45. https://
doi.org/10.1093/europace/eur364.
27. PARIKH SS, JONS C, MCNITT S, DAUBERT JP, SCHWARZ
KQ, HALL B. Predictive capability of left atrial size measured by
CT, TEE, and TTE for recurrence of atrial fibrillation following
radiofrequency catheter ablation. Pacing Clin Electrophysiol.
2010;33(5):532–40. https://doi.org/10.1111/j.1540-8159.2010.
02693.x.
28. Antonielli E, Pizzuti A, Pálinkás A, et al. Clinical value of left atrial
appendage flow for prediction of long-term sinus rhythm mainte-
nance in patients with nonvalvular atrial fibrillation. J Am Coll
Cardiol. 2002;39(9):1443-1449. http://www.ncbi.nlm.nih.gov/
pubmed/11985905. Accessed March 3, 2019.
29. Okçün B, Yigit Z, KüçükogluMS, et al. Predictors for maintenance
of sinus rhythm after cardioversion in patients with nonvalvular
atrial fibrillation. Echocardiography. 2002;19(5):351-357. http://
www.ncbi.nlm.nih.gov/pubmed/12174197. Accessed March 3,
2019.
30. Calkins H, Kuck KH, Cappato R, et al. 2012 HRS/EHRA/ECAS
expert consensus statement on catheter and surgical ablation of
atrial fibrillation: recommendations for patient selection, procedural
techniques, patient management and follow-up, definitions, end-
points, and research trial design. Hear Rhythm. 2012;9(4):632-
696.e21. https://doi.org/10.1016/j.hrthm.2011.12.016.
31. Y-C LIAO, J-N LIAO, L-W LO, et al. Left atrial size and left
ventricular end-systolic dimension predict the progression of par-
oxysmal atrial fibrillation after catheter ablation. J Cardiovasc
Electrophysiol. 2017;28(1):23–30. https://doi.org/10.1111/jce.
13115.
32. Olshansky B, Heller EN,Mitchell LB, et al. Are transthoracic echo-
cardiographic parameters associated with atrial fibrillation recur-
rence or stroke? J Am Coll Cardiol. 2005;45(12):2026–33. https://
doi.org/10.1016/j.jacc.2005.03.020.
33. Lang RM, Bierig M, Devereux RB, et al. Recommendations for
chamber quantification: a report from the American Society of
Echocardiography’s guidelines and standards committee and the
Chamber Quantification Writing Group, developed in conjunction
with the European Association of Echocardiograph. J Am Soc
Echocardiogr. 2005;18(12):1440–63. https://doi.org/10.1016/j.
echo.2005.10.005.
34. Mor-Avi V, Yodwut C, Jenkins C, et al. Real-time 3D echocardio-
graphic quantification of left atrial volume: multicenter study for
validation with CMR. JACC Cardiovasc Imaging. 2012;5(8):769–
77. https://doi.org/10.1016/j.jcmg.2012.05.011.
35. Badano LP, Pezzutto N, Marinigh R, et al. How many patients
would be misclassified using M-mode and two-dimensional esti-
mates of left atrial size instead of left atrial volume? A three-
dimensional echocardiographic study. J Cardiovasc Med.
2 008 ; 9 ( 5 ) : 4 7 6–84 . h t t p s : / / d o i . o r g / 1 0 . 2 45 9 / JCM .
0b013e3282f194f0.
36. Zhang Q, Wang J, Dong Q, et al. Evaluation of left atrial volume
and function using single-beat real-time three-dimensional echocar-
diography in atrial fibrillation patients. BMC Med Imaging.
2017;17(1):44. https://doi.org/10.1186/s12880-017-0215-7.
37. Ellis D, Rangaraju S, Duncan A, et al. Coagulation markers and
echocardiography predict atrial fibrillation, malignancy or recurrent
stroke after cryptogenic stroke. Medicine (Baltimore). 2018;97(51):
e13830. https://doi.org/10.1097/MD.0000000000013830.
38. Kang M-K, Joung B, Shim CY, et al. Post-operative left atrial vol-
ume index is a predictor of the occurrence of permanent atrial fi-
brillation after mitral valve surgery in patients who undergo mitral
valve surgery. Cardiovasc Ultrasound. 2018;16(1):5. https://doi.
org/10.1186/s12947-018-0123-1.
39. Marchese P, Malavasi V, Rossi L, et al. Indexed left atrial volume is
superior to left atrial diameter in predicting nonvalvular atrial fibril-
lation recurrence after successful cardioversion: a prospective study.
Echocardiography. 2012;29(3):276–84. https://doi.org/10.1111/j.
1540-8175.2011.01580.x.
40. Moon J, Hong YJ, Shim J, et al. Right atrial anatomical remodeling
affects early outcomes of nonvalvular atrial fibrillation after
43 Page 10 of 12 Curr Cardiovasc Imaging Rep (2019) 12: 43
radiofrequency ablation. Circ J. 2012;76(4):860-867. http://www.
ncbi.nlm.nih.gov/pubmed/22293450. Accessed March 3, 2019.
41. Kotecha D, Mohamed M, Shantsila E, Popescu BA, Steeds RP. Is
echocardiography valid and reproducible in patients with atrial fi-
brillation? A systematic review. Europace. 2017;19(9):1427–38.
https://doi.org/10.1093/europace/eux027.
42. Shaikh AY, Maan A, Khan UA, et al. Speckle echocardiographic
left atrial strain and stiffness index as predictors of maintenance of
sinus rhythm after cardioversion for atrial fibrillation: a prospective
study. Cardiovasc Ultrasound. 2012;10(1):1. https://doi.org/10.
1186/1476-7120-10-48.
43. Machino-Ohtsuka T, Seo Y, Ishizu T, et al. Significant improvement
of left atrial and left atrial appendage function after catheter ablation
for persistent atrial fibrillation. Circ J. 2013;77(7):1695–704.
https://doi.org/10.1253/circj.cj-12-1518.
44. Motoki H, Negishi K, Kusunose K, et al. Global left atrial strain in
the prediction of sinus rhythm maintenance after catheter ablation
for atrial fibrillation. J Am Soc Echocardiogr. 2014;27(11):1184–
92. https://doi.org/10.1016/j.echo.2014.08.017.
45. Hammerstingl C, SchwekendiekM,Momcilovic D, et al. Left atrial
deformation imaging with ultrasound based two-dimensional
speckle-tracking predicts the rate of recurrence of paroxysmal and
persistent atrial fibrillation after successful ablation procedures. J
Cardiovasc Electrophysiol. 2012;23(3):247–55. https://doi.org/10.
1111/j.1540-8167.2011.02177.x.
46. Shih J-Y, Tsai W-C, Huang Y-Y, et al. Association of decreased left
atrial strain and strain rate with stroke in chronic atrial fibrillation. J
AmSoc Echocardiogr. 2011;24(5):513–9. https://doi.org/10.1016/j.
echo.2011.01.016.
47. Candan O, Ozdemir N, Aung SM, et al. Left atrial longitudinal
strain parameters predict postoperative persistent atrial fibrillation
following mitral valve surgery: a speckle tracking echocardiogra-
phy study. Echocardiography. 2013;30(9):n/a-n/a. https://doi.org/
10.1111/echo.12222.
48. Ancona R, Comenale Pinto S, Caso P, et al. Two-dimensional atrial
systolic strain imaging predicts atrial fibrillation at 4-year follow-up
in asymptomatic rheumatic mitral stenosis. J Am Soc Echocardiogr.
2013;26(3):270–7. https://doi.org/10.1016/j.echo.2012.11.016.
49. Gabrielli L, Corbalan R, Córdova S, et al. Left atrial dysfunction is a
predictor of postcoronary artery bypass atrial fibrillation: associa-
tion of left atrial strain and strain rate assessed by speckle tracking.
Echocardiography. 2011;28(10):1104–8. https://doi.org/10.1111/j.
1540-8175.2011.01518.x.
50. Her AY, Kim JY, Kim YH, et al. Left atrial strain assessed by
speckle tracking imaging is related to new-onset atrial fibrillation
after coronary artery bypass grafting. Can J Cardiol. 2013;29(3):
377–83. https://doi.org/10.1016/j.cjca.2012.06.006.
51. Shavarov AA, Yusupov AA, Kiyakbaev GK, Vasyuk YA, Moiseev
VS. Left atrial remodeling and thromboembolic risk in patients with
recurrent atrial fibrillation. Kardiologiia. 2015;55(11):37-44. http://
www.ncbi.nlm.nih.gov/pubmed/27125103. AccessedMay 6, 2019.
52. Pagola J, González-Alujas T, Flores A, et al. Left atria strain is a
surrogate marker for detection of atrial fibrillation in cryptogenic
strokes. Stroke. 2014;45(8):164–6. https://doi.org/10.1161/
strokeaha.114.005540.
53. Marino PN, Degiovanni A, Baduena L, et al. Non-invasively esti-
mated left atrial stiffness is associated with short-term recurrence of
atrial fibrillation after electrical cardioversion. J Cardiol.
2017;69(5):731–8. https://doi.org/10.1016/j.jjcc.2016.07.013.
54. Dell’Era G, Rondano E, Franchi E, Marino PN. Atrial asynchrony
and function before and after electrical cardioversion for persistent
atrial fibrillation. Eur J Echocardiogr. 2010;11(7):577–83. https://
doi.org/10.1093/ejechocard/jeq010.
55. Doruchowska A, Wita K, Bochenek T, et al. Role of left atrial
speckle tracking echocardiography in predicting persistent atrial
fibrillation electrical cardioversion success and sinus rhythm
maintenance at 6 months. Adv Med Sci. 2014;59(1):120–5.
https://doi.org/10.1016/j.advms.2013.10.003.
56. Sarvari SI, Haugaa KH, Stokke TM, et al. Strain echocardiographic
assessment of left atrial function predicts recurrence of atrial fibril-
lation. Eur Heart J Cardiovasc Imaging. 2016;17(6):660–7. https://
doi.org/10.1093/ehjci/jev185.
57. Bernard-Brunet A, Saint Etienne C, Piver E, et al. Incomplete re-
covery of mechanical and endocrine left atrial functions one month
after electrical cardioversion for persistent atrial fibrillation: a pilot
study. J Transl Med. 2014;12(1):2–9. https://doi.org/10.1186/1479-
5876-12-51.
58. Marino P, Little WC, Rossi A, et al. Can left ventricular diastolic
stiffness be measured noninvasively? J Am Soc Echocardiogr.
2002;15(9):935-943. http://www.ncbi.nlm.nih.gov/pubmed/
12221410. Accessed May 6, 2019.
59. Fu H, Liu T, Zhou C, Zheng C, Li G. Two-dimensional speckle
tracking echocardiography: a novel approach to evaluate left atrial
mechanical function. Int J Cardiol. 2012;155(3):481–2. https://doi.
org/10.1016/j.ijcard.2011.12.072.
60. Jarasunas J, Aidietis A, Aidietiene S. Left atrial strain - an early
marker of left ventricular diastolic dysfunction in patients with hy-
pertension and paroxysmal atrial fibrillation. Cardiovasc
Ultrasound. 2018;16(1):29. https://doi.org/10.1186/s12947-018-
0147-6.
61. Kupczynska K, Michalski BW, Miskowiec D, et al. Association
between left atrial function assessed by speckle-tracking echocardi-
ography and the presence of left atrial appendage thrombus in pa-
tients with atrial fibrillation. Anatol J Cardiol. 2017;18(1):15–22.
https://doi.org/10.14744/AnatolJCardiol.2017.7613.
62. Allessie M, Ausma J, Schotten U. Electrical, contractile and struc-
tural remodeling during atrial fibrillation. Cardiovasc Res.
2002;54(2):230-246. http://www.ncbi.nlm.nih.gov/pubmed/
12062329. Accessed March 6, 2019.
63. Platonov PG, Mitrofanova LB, Orshanskaya V, Ho SY. Structural
abnormalities in atrial walls are associated with presence and per-
sistency of atrial fibrillation but not with age. J Am Coll Cardiol.
2011;58(21):2225–32. https://doi.org/10.1016/j.jacc.2011.05.061.
64. Teh AW, Kistler PM, Lee G, et al. Long-term effects of catheter
ablation for lone atrial fibrillation: progressive atrial electroanato-
mic substrate remodeling despite successful ablation. Hear Rhythm.
2012;9(4):473–80. https://doi.org/10.1016/j.hrthm.2011.11.013.
65. Leung M, Abou R, van Rosendael PJ, et al. Relation of echocar-
diographic markers of left atrial fibrosis to atrial fibrillation burden.
Am J Cardiol. 2018;122(4):584–91. https://doi.org/10.1016/j.
amjcard.2018.04.047.
66. AntoniML, BertiniM, Atary JZ, et al. Predictive value of total atrial
conduction time estimated with tissue doppler imaging for the de-
velopment of new-onset atrial fibrillation after acute myocardial
infarction. Am J Cardiol. 2010;106(2):198–203. https://doi.org/10.
1016/j.amjcard.2010.02.030.
67. Müller P, Ivanov V, Kara K, et al. Total atrial conduction time to
predict occult atrial fibrillation after cryptogenic stroke. Clin Res
Cardiol. 2017;106(2):113–9. https://doi.org/10.1007/s00392-016-
1029-2.
68. ZhouY, Chen J, Hu B, Cao S, ZhouQ, Guo R. The predictive value
of intra-left atrial mechanical delay for 1-year recurrence of atrial
fibrillation after catheter ablation: a clinical follow-up study using
dual Doppler echocardiography. J Clin Ultrasound. 2018;46(8):
519–26. https://doi.org/10.1002/jcu.22629.
69. Ari H, Ari S, Sarigül OY, et al. A novel index combining diastolic
and systolic tissue doppler parameters for prediction of atrial fibril-
lation recurrence. Echocardiography. 2016;33(7):1009–15. https://
doi.org/10.1111/echo.13212.
70. Beigel R, Wunderlich NC, Ho SY, Arsanjani R, Siegel RJ. The left
atrial appendage: anatomy, function, and noninvasive evaluation.
Curr Cardiovasc Imaging Rep (2019) 12: 43 Page 11 of 12 43
JACC Cardiovasc Imaging. 2014;7(12):1251–65. https://doi.org/
10.1016/j.jcmg.2014.08.009.
71. Di Biase L, Santangeli P, Anselmino M, et al. Does the left atrial
appendage morphology correlate with the risk of stroke in patients
with atrial fibrillation? J Am Coll Cardiol. 2012;60(6):531–8.
https://doi.org/10.1016/j.jacc.2012.04.032.
72. Mikael Kortz RA, Delemarre BJ, van Dantzig JM, Bot H, Kamp O,
Visser CA. Left atrial appendage blood flow determined by trans-
esophageal echocardiography in healthy subjects. Am J Cardiol.
1993;71(11):976-981. http://www.ncbi.nlm.nih.gov/pubmed/
8465792. Accessed May 6, 2019.
73. Fatkin D, Kelly RP, Feneley MP. Relations between left atrial ap-
pendage blood flow velocity, spontaneous echocardiographic con-
trast and thromboembolic risk in vivo. J Am Coll Cardiol.
1994;23(4):961-969. http://www.ncbi.nlm.nih.gov/pubmed/
8106703. Accessed May 6, 2019.
74. Goldberg YH, Gordon SC, Spevack DM, Gordon GM. Disparities
in emptying velocity within the left atrial appendage. Eur J
Echocardiogr. 2010;11(3):290–5. https://doi.org/10.1093/
ejechocard/jep216.
75. Ono K, Iwama M, Kawasaki M, et al. Motion of left atrial append-
age as a determinant of thrombus formation in patients with a low
CHADS2 score receiving warfarin for persistent nonvalvular atrial
fibrillation. Cardiovasc Ultrasound. 2012;10(1):1. https://doi.org/
10.1186/1476-7120-10-50.
76. Iwama M, Kawasaki M, Tanaka R, et al. Left atrial appendage
emptying fraction assessed by a feature-tracking echocardiographic
method is a determinant of thrombus in patients with nonvalvular
atrial fibrillation. J Cardiol. 2012;59(3):329–36. https://doi.org/10.
1016/j.jjcc.2012.01.002.
77. Uretsky S, Shah A, Bangalore S, et al. Assessment of left atrial
appendage function with transthoracic tissue Doppler echocardiog-
raphy. Eur J Echocardiogr. 2009;10(3):363–71. https://doi.org/10.
1093/ejechocard/jen339.
78. DONAL E, SALLACH J, DANIELMURRAY R, et al. Contrast-
enhanced tissue Doppler imaging of the left atrial appendage is a
new quantitative measure of spontaneous echocardiographic con-
trast in atrial fibrillation. Eur J Echocardiogr. 2006;9(1):5–11.
https://doi.org/10.1016/j.euje.2006.10.001.
79. Anwar AM, Nosir YFM, Ajam A, Chamsi-Pasha H. Central role of
real-time three-dimensional echocardiography in the assessment of
intracardiac thrombi. Int J Cardiovasc Imaging. 2010;26(5):519–
26. https://doi.org/10.1007/s10554-010-9593-4.
80. Nucifora G, Faletra FF, Regoli F, et al. Evaluation of the left atrial
appendage with real-time 3-dimensional transesophageal echocar-
diography. Circ Cardiovasc Imaging. 2011;4(5):514–23. https://doi.
org/10.1161/CIRCIMAGING.111.963892.
81. Agoston I, Xie T, Tiller FL, Rahman AM, AhmadM. Assessment of
left atrial appendage by live three-dimensional echocardiography:
early experience and comparison with transesophageal echocardiog-
raphy. Echocardiography. 2006;23(2):127–32. https://doi.org/10.
1111/j.1540-8175.2006.00181.x.
82. Perk G, Biner S, Kronzon I, et al. Catheter-based left atrial append-
age occlusion procedure: role of echocardiography. Eur Hear J -
Cardiovasc Imaging. 2012;13(2):132–8. https://doi.org/10.1093/
ejechocard/jer158.
83. Shah SJ, Bardo DME, Sugeng L, et al. Real-time three-dimensional
transesophageal echocardiography of the left atrial appendage: ini-
tial experience in the clinical setting. J Am Soc Echocardiogr.
2008;21(12):1362–8. https://doi.org/10.1016/j.echo.2008.09.024.
84. Hart RG, Sharma M, Mundl H, et al. Rivaroxaban for stroke pre-
vention after embolic stroke of undetermined source. N Engl JMed.
2018 ; 378 ( 23 ) : 2191–201 . h t t p s : / / d o i . o rg / 10 . 1056 /
NEJMoa1802686.
85. Diener H-C, Sacco RL, Easton JD, et al. Dabigatran for prevention
of stroke after embolic stroke of undetermined source. N Engl J
Med. 2019;380(20):1906–17. https://doi.org/10.1056/
NEJMoa1813959.
86. Healey JS, Gladstone DJ, Swaminathan B, et al. Recurrent stroke
with rivaroxaban compared with aspirin according to predictors of
atrial fibrillation: secondary analysis of the NAVIGATE ESUS ran-
domized clinical trial. JAMA Neurol. 2019. https://doi.org/10.
1001/jamaneurol.2019.0617.
87. Chao T-F, Lip GYH, Lin Y-J, et al. Age threshold for the use of non-
vitamin K antagonist oral anticoagulants for stroke prevention in
patients with atrial fibrillation: insights into the optimal assessment
of age and incident comorbidities. Eur Heart J. 2019. https://doi.org/
10.1093/eurheartj/ehy837.
Publisher’s Note Springer Nature remains neutral with regard to
jurisdictional claims in published maps and institutional affiliations.
43 Page 12 of 12 Curr Cardiovasc Imaging Rep (2019) 12: 43
